Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

coccidioidomycosis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

coccidioidomycosis

MONDO:0005706

Also known as:California diseaseCoccidioides immitis caused disease or disorderCoccidioides immitis disease or disorder

Find Clinical TrialsTrials

Overview

A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.

TreatmentsNo approved treatments · 6 in pipeline

Clinical Trials8 registered · 2 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include common findings: Fever, Pneumonia, Immunodeficiency, and Increased circulating IgG concentration and others; and sometimes findings: Nervous system problems (abnormality of the nervous system), Atypical scarring of skin, Skin rash, and Pruritus and others. 76 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	10	Nervous system problems (abnormality of the nervous system), Fatigue, Hydrocephalus

Diagnosis

Biomarker and diagnostic research for coccidioidomycosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for coccidioidomycosis. An additional 6 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for coccidioidomycosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for coccidioidomycosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Phenotype severity distribution: 5 common features.

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

8 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 4 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06925919](https://clinicaltrials.gov/study/NCT06925919)

Data assembled from 6 of 12 sources · Last updated Oct 4, 2026, 12:14 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:228123

GARD

Genetic and Rare Diseases Info Center

GARD:9525

Questions for Your Care Team

→Are any of the 8 active clinical trials a good fit for my situation?
→With 6 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	73	28%
Disease patterns and progression	72	28%
Research summaries	38	15%
Laboratory research	35	14%
Testing and diagnosis research	22	9%
Clinical study results	9	3%
Other research	5	2%
New treatment approaches	4	2%

Kisho

coccidioidomycosis

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Skeletal coccidioidomycosis: an atypical pediatric presentation.

Neonatal management and outcomes in the setting of disseminated coccidioidomycosis in pregnancy.

Exhausted T cell phenotypes in disseminated coccidioidomycosis.

Regional Increases in Incidence of Coccidioidomycosis (Valley Fever) — Arizona, 2005–2022

coccidioidomycosis

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Skeletal coccidioidomycosis: an atypical pediatric presentation.

Neonatal management and outcomes in the setting of disseminated coccidioidomycosis in pregnancy.

Exhausted T cell phenotypes in disseminated coccidioidomycosis.

Regional Increases in Incidence of Coccidioidomycosis (Valley Fever) — Arizona, 2005–2022